Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomarin Pharmaceuticals
(NQ:
BMRN
)
69.51
+1.35 (+1.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biomarin Pharmaceuticals
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
BioMarin Achieves Record Q1 Sales Driven By Recently Approved Achondroplasia Therapy
April 28, 2022
Via
Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
April 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Biomarin Pharmaceutical Earnings Preview
April 26, 2022
Biomarin Pharmaceutical (NASDAQ:BMRN) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
10 Biggest Price Target Changes For Monday
April 25, 2022
Keybanc cut Salesforce, Inc. (NYSE: CRM) price target from $281 to $223. Salesforce shares fell 1.1% to $169.60 in pre-market trading.
Via
Benzinga
BioMarin Stock Dives As FDA Questions The Safety Of Its Gene Therapy
February 18, 2022
BioMarin needs to run additional testing in animal models for its PKU gene therapy.
Via
Investor's Business Daily
BioMarin Sells Priority Review Voucher For $110M
February 09, 2022
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has agreed to sell the Rare Pediatric Disease Priority Review Voucher (PRV)
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
April 25, 2022
Via
Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
April 24, 2022
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...
Via
Benzinga
A Bearish Sign Appears On Biomarin Pharmaceutical's Chart
April 21, 2022
If history is any guide, there may be trouble ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish...
Via
Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market
February 24, 2022
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 1% Y/Y decrease in Q4 revenue to $449.8 million, beating the consensus estimate of $442.39 million. The decline...
Via
Benzinga
Recap: Biomarin Pharmaceutical Q4 Earnings
February 23, 2022
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
February 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...
Via
Benzinga
FDA Asks For More Data To Resolve BioMarin's Gene Therapy Clinical Hold
February 18, 2022
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) said that the FDA had requested additional information regarding the clinical hold on PHEARLESS Phase 1/2 study of BMN...
Via
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Bear Market Bets In Biotech
February 07, 2022
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020.
Via
Talk Markets
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.
February 03, 2022
Wilmington, Delaware--(Newsfile Corp. - February 3, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors...
Via
Newsfile
Exposures
Product Safety
Futures Resume Tumbling After Yields Spike To New 2 Year High
January 10, 2022
US index futures traded down to session lows as US traders sat at their desks after rising modestly earlier in the session, and were down 27 points or 0.6% at 730am.
Via
Talk Markets
BioMarin's Hemophilia Gene Therapy Meets Efficacy Endpoints At Two Year Analysis
January 10, 2022
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) announced results from its ongoing Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, investigational gene therapy for severe...
Via
Benzinga
BioMarin Class Action Reminder
December 31, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
BioMarin Shareholder Notice
December 30, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
BioMarin Shareholder Alert
December 29, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
BioMarin Deadline Alert
December 28, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
BioMarin Deadline Alert
December 24, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
BioMarin Deadline Alert
December 22, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Final Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. (BMRN) Investors of Class Action
December 22, 2021
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Deadline Tomorrow Alert: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
December 20, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Deadline Notice: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
December 17, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
December 16, 2021
Los Angeles - (NewMediaWire) - December 16, 2021 - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioMarin Pharmaceutical Inc....
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.